ZYDUSLIFE Zydus Lifesciences Ltd Product Launches Announcement 2025 - FDA Approval Received Zydus Lifesciences Ltd has received USFDA approval for Dasatinib Tablets in various dosages, including 20 mg to 140 mg, aimed at treating specific types of leukemia. This approval was announced on March 5, 2025, and the tablets will be manufactured in Ahmedabad, with annual US sales of Dasatinib reaching USD 1807.7 million..Find Corporate Announcements for Press Releases, AGM, Insider Trading & SAST, Results and Corporate Action for Zydus Lifesciences Ltd